(Newswise)–While Lyme disease is the most recognized and prevalent tick-borne disease in the United States, other infections transmitted through tick bites can be equally or even more dangerous.
One of these is the Powassan virus (POWV). Erich Mackow, Ph.D., an internationally recognized virologist at Stony Brook University, is researching to uncover one of the most dangerous effects of POWV – neurologic damage.
Powassan virus is endemic to North America. It is present in about two percent of Long Island ticks and is injected into the skin during just a 15-minute tick bite. POWV-infected patients have a 10 percent risk of fatal encephalitis and up to 50 percent of infected patients have long-term neurologic damage. Severe neurologic symptoms are associated with POWV infection in older patients.
Mackow is a Professor in the Department of Microbiology and Immunology in the Renaissance School of Medicine (RSOM), a core member of Stony Brook’s Center for Infectious Diseases, and among several scientists at Stony Brook University investigating ways to target treatments of tick-borne infections better. Stony Brook Medicine has a clinic that treats Lyme disease and all tick-borne infections, such as POWV, and is home to the Regional Tick-Borne Disease Resource Center.
“The severity of Powassan encephalitis in the elderly remains an enigma as the mechanisms of the viral neuroinvasion remain virtually unknown,” says Mackow.
For this research, Mackow and his RSOM colleagues focus their investigation on analyzing all aspects of the neurological effects of POWV, defining viral proteins that direct neurovirulence, developing therapeutics and attenuated POWV vaccines, and assessing the role of cell senescence, the biological process when cells stop dividing, as an age-dependent cause of POWV encephalitis.
The team isolated a Powassan virus strain (L19) from ticks on Long Island and developed an animal model of POWV-induced encephalitis and age-dependent lethality. They established a mechanism for genetically altering POWV, and generated attenuated viral mutants that as vaccine candidates fail to cause disease and elicit protective immune responses.
Vaccines and therapeutic approaches for preventing POWV neuroinvasion are now being examined by researchers and the role of age in the severity of POWV infection revealed.
“Our findings provide a foundational basis to understanding the mechanism of neurovirulent pathogens in the central nervous system, define the role of brain senescence in disease severity, and the potential to use responses that protect young mice from POWV lethality to develop targeted human therapeutics that protect the elderly from lethal POWV infections,” explains Mackow.
The investigators detail their discovery based on the age-dependent model and novel POWV genetics in a new paper published this month in the Journal of Virology.
The authors write that their laboratory results establish the age-dependent lethality of POWV in a murine model that mirrors human POWV severity and long-term central nervous system pathology in the elderly.
Mackow, the lead author, said that only minimal infectious doses of the virus were highly lethal in older mice and that lethality increased >10-fold with age. The researchers also determined that POWV lethality is linked to central nervous system glial cell activation and age-dependent neuroinflammatory cytokine responses in the mice, establishing mechanisms contributing to Powassan virus encephalitis.
Ongoing research supported by $9 million in grant funding
Mackow’s research is supported by a Department of Defense grant and three new National Institutes of Health grants from the National Institute of Allergy and Infectious Diseases. The grants total $8 million over five years and the Department of Defense grant provides approximately $9 million in funding through August 2029.
The research covered by the grants aims to understand POWV-defining mechanisms of POWV entry into the brain of its host, age-dependent responses that increase disease severity, and the development of therapeutics and vaccines against the virus.
